Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 8 at 2:00 PM EDT

Register Free →

Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Cancer Institute (NCI) is inviting research proposals through the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program, which focuses on identifying and exploiting synthetic vulnerabilities in tumors that arise specifically in response to radiation therapy. This initiative aims to develop novel radiation-synthetic drug combination strategies to improve precision medicine approaches in cancer treatment. Emphasizing the adaptive and context-dependent nature of tumor responses to radiation, the program seeks to move beyond fixed genetic targets by leveraging alterations induced by radiation that create or enhance targets for molecular therapies, ultimately improving therapeutic outcomes. The PAIRS program encourages innovative research combining radiation therapy with targeted agents to exploit tumor-specific vulnerabilities while minimizing harm to healthy tissues, thereby increasing the therapeutic index. The solicitation consolidates previous exploratory and research funding opportunities into a streamlined application process, offering support for exploratory projects lasting up to two years or full research projects ranging from four to five years. Radiation dosing, scheduling, and spatial delivery flexibility are key factors in this precision approach, and the program underscores scientific rigor, reproducibility, and alignment with NIH priorities. Interested applicants can seek guidance through the NCI PAIRS Program contact points provided for further support.

General Info

NCI PAIRS program funds research on radiation-induced tumor vulnerabilities for precise cancer drug combinations.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
Office AddressUS
Contacts

Full Description

Show more

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments. Early synthetic lethality–based therapeutic strategies in oncology primarily focused on targeting fixed mutations or genomic abnormalities. More recently, however, it has become clear that clinical benefit is often determined by context-dependent vulnerabilities arising from the intrinsic mutational landscape and adaptive tumor responses.

This NOFO is unique in its scope, supporting innovative cancer therapy strategies that explicitly exploit context-dependent effects of radiation therapy (RT) using drug-radiation combinations. The central premise of the PAIRS is that these conditional RT-induced responses can be leveraged to create or enhance actionable vulnerabilities that synergize with molecularly targeted agents for better outcomes. A defining feature of PAIRS is its emphasis on precision, scientific rigor, and reproducibility, aligned with NIH’s scientific priorities. Radiation effects are clinically titratable through advances in delivery accuracy and flexibility, including dose, schedule, and spatial targeting. These capabilities enable the rational design of conditional RT-synthetic combination strategies that preferentially exploit tumor-specific essentialities while sparing normal tissues, thereby enhancing the therapeutic index by optimizing biological response. This NOFO consolidates the prior exploratory/developmental and research project funding opportunities to streamline the application process and maintain momentum in developing approaches that target actionable vulnerabilities within the defined radiation research scope. The applicants may submit either for exploratory/developmental research projects with a project period of up to 2 years or for research projects with a project period of 4 to 5 years. 

 

Similar Contracts

NAICS: 541714
New
Federal
Exosome Purification, Exosomal RNA Purification, and Small RNA-Sequencing ServicesThe National Institutes of Health, in collaboration with the National Institute on Alcohol Abuse and Alcoholism and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, seeks specialized laboratory services to support the POTS clinical research study conducted at NIH in Bethesda, Maryland. The contract requires a qualified provider to process 31 irreplaceable plasma specimens from human participants, performing integrated exosome isolation, exosomal RNA purification, and small RNA-sequencing using Illumina platforms. These tasks must be completed with strict adherence to sample integrity and chain of custody protocols, as the requiring laboratory lacks the validated capacity or bandwidth to perform these procedures in-house within the required timeframe. Each specimen, consisting of 0.5 mL of plasma, must be processed to yield intact exosomes split into multiple aliquots, with exosomal RNA extracted and_QUALITY controlled, and a portion used for downstream sequencing. The contractor is responsible for supplying all personnel, equipment, reagents, and materials necessary to complete the work. The provider must prepare libraries, sequence all 31 samples on the Illumina platform with a target of approximately 20 million raw reads per sample at 1x51 bp, and deliver sequencing data to the government via both physical hard drive and digital download. Basic bioinformatics processing, including read trimming, filtering, and mapping, is also required to ensure analysis-ready outputs. All specimens and resulting materials must be returned to the NIH in accordance with prescribed protocols, maintaining proper documentation and tracking throughout the entire workflow. The solicitation, numbered 75N98026Q00707, is open for response until July 7, 2026, under NAICS code 541714, with no set-aside requirements, and point of contact for inquiries is John Burton at NIH.
National Institutes Of Health Olao

POSTED

4 days ago

DEADLINE

in 8 days
View Details
NAICS: 541714
New
Federal
AJ12--Special Notice | Intent to Sole Source | Biostatistics Support for Prostate Cancer Analysis for Treatment Choice (PATCH) Clinical Trials ConsortiumThe Veterans Health Administration, Network Contracting Office 5, intends to award a sole source contract to CANCER RESEARCH & BIOSTATISTICS for biostatistics support services related to the Prostate Cancer Analysis for Treatment Choice (PATCH) Clinical Trials Consortium. The vendor will deliver expert analytical and consulting services to all member institutions of the Precision Oncology Program for Cancer of the Prostate and select sites within the Lung Precision Oncology Program. The work is essential for advancing clinical trial data interpretation and treatment optimization in prostate cancer research within the VA healthcare system. The contract will be issued under FAR Subpart 13.106-1(b), reflecting the government’s determination that only this vendor possesses the unique expertise required to fulfill the requirement. This notice is not a solicitation for competitive bids, but any capable responsible source may submit a capability statement, proposal, or quotation prior to the deadline of July 12, 2026, at 12:00 PM Eastern Time. The government retains full discretion to determine whether to proceed with sole source award based on any submissions received. The action is categorized under NAICS code 541714 for scientific research and development services, and all communications must be directed to Contracting Officer Ethan Mauzy at the Department of Veterans Affairs office in Linthicum, Maryland. The solicitation number is 36C24526Q0624, and details are accessible via the SAM.gov website.
245-NETWORK Contract Office 5 (36C245)

POSTED

4 days ago

DEADLINE

in 12 days
View Details